Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

Research Watch

Recoding RNA Editing of AZIN1 Is Oncogenic in Hepatocellular Carcinoma

DOI: 10.1158/2159-8290.CD-RW2013-017 Published March 2013
  • Article
  • Info & Metrics
Loading
  • Major finding: RNA editing of AZIN1 is increased in HCC and enhances tumor incidence and progression.

  • Mechanism: Edited AZIN1 promotes proliferation by blocking antizyme-mediated degradation of ODC and CCND1.

  • Impact: Adenosine-to-inosine recoding of AZIN1 confers a gain of function that drives tumorigenesis.

RNA editing is a regulatory mechanism in which nucleotides are altered posttranscriptionally and most frequently involves conversion of adenosine to inosine, which is recognized as a guanosine during translation. Chen and colleagues performed RNA sequencing analysis to identify molecular changes in hepatocellular carcinoma (HCC) samples that might contribute to disease progression, and they detected elevated adenosine-to-inosine RNA editing of antizyme inhibitor 1 (AZIN1) in HCC samples compared with adjacent normal tissues. The frequency of AZIN1 editing increased during HCC progression and was correlated with liver cirrhosis, tumor recurrence, and poor prognosis, suggesting that this recoding event may promote HCC pathogenesis. AZIN1 RNA modification was mediated by the p110 isoform of adenosine deaminase, RNA-specific (ADAR1), but not by other ADAR family members, and resulted in substitution of glycine for serine at residue 367 in the AZIN1 protein, which was predicted to induce a conformational switch. This amino acid change triggered cytoplasmic-to-nuclear translocation of AZIN1 in HCC samples and conferred a gain-of-function phenotype in tumor cell lines; expression of edited AZIN1 increased cell proliferation, anchorage-independent growth, and invasion and augmented tumor incidence in mice, supporting a protumorigenic function for this edited protein. Mechanistically, edited AZIN1 exhibited increased binding affinity for antizyme, a tumor suppressor that inhibits proliferation, and enhanced protein stability compared with wild-type AZIN1. Moreover, edited AZIN1 impaired antizyme-mediated proteasomal degradation of the oncoproteins ornithine decarboxylase 1 (ODC1) and cyclin D1 (CCND1), thus stimulating retinoblastoma (RB) phosphorylation and cell-cycle entry in xenograft-derived tumor cells. These results establish liver-specific RNA editing of AZIN1 as an oncogenic event that modulates AZIN1 protein function and drives tumor initiation and progression in HCC.

Chen L, Li Y, Lin CH, Chan TH, Chow RK, Song Y, et al. Recoding RNA editing of AZIN1 predisposes to hepatocellular carcinoma. Nat Med 2013 Jan 6 [Epub ahead of print].

  • ©2013 American Association for Cancer Research.
View Abstract
PreviousNext
Back to top
Cancer Discovery: 3 (3)
March 2013
Volume 3, Issue 3
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Recoding RNA Editing of AZIN1 Is Oncogenic in Hepatocellular Carcinoma
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Recoding RNA Editing of AZIN1 Is Oncogenic in Hepatocellular Carcinoma
Cancer Discov March 1 2013 (3) (3) OF12; DOI: 10.1158/2159-8290.CD-RW2013-017

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Recoding RNA Editing of AZIN1 Is Oncogenic in Hepatocellular Carcinoma
Cancer Discov March 1 2013 (3) (3) OF12; DOI: 10.1158/2159-8290.CD-RW2013-017
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Research Watch

  • Structures Identify Selpercatinib and Pralsetinib Resistance Mechanisms
  • Computational Tool Characterizes Previously Unidentified Tumor Subtypes
  • Deep Learning Algorithm Aids Breast Cancer Detection by Mammography
Show more Research Watch

Hepatocellular Carcinoma

  • Obesity Independently Drives NASH and Hepatocellular Carcinoma
  • Inflammation-Induced IgA+ Cells Promote Hepatocellular Tumorigenesis
  • ARID1A Has Context-Specific Roles in Hepatocellular Carcinoma
Show more Hepatocellular Carcinoma
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement